JP2008518924A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008518924A5 JP2008518924A5 JP2007539148A JP2007539148A JP2008518924A5 JP 2008518924 A5 JP2008518924 A5 JP 2008518924A5 JP 2007539148 A JP2007539148 A JP 2007539148A JP 2007539148 A JP2007539148 A JP 2007539148A JP 2008518924 A5 JP2008518924 A5 JP 2008518924A5
- Authority
- JP
- Japan
- Prior art keywords
- carbons
- alkyl
- pharmaceutical composition
- hydrogen
- injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 3-ethoxy-4-methoxy-phenyl Chemical group 0.000 claims 25
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 8
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 208000001738 Nervous System Trauma Diseases 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 210000003169 central nervous system Anatomy 0.000 claims 5
- 208000028412 nervous system injury Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 208000020431 spinal cord injury Diseases 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 208000029028 brain injury Diseases 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- 206010052346 Brain contusion Diseases 0.000 claims 1
- 208000006569 Central Cord Syndrome Diseases 0.000 claims 1
- 208000000202 Diffuse Axonal Injury Diseases 0.000 claims 1
- 206010018852 Haematoma Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 206010036312 Post-traumatic epilepsy Diseases 0.000 claims 1
- 206010049679 Spinal shock Diseases 0.000 claims 1
- 208000002667 Subdural Hematoma Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 229960002319 barbital Drugs 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 230000009516 brain contusion Effects 0.000 claims 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims 1
- 229960002495 buspirone Drugs 0.000 claims 1
- 206010007821 cauda equina syndrome Diseases 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims 1
- 230000009521 diffuse axonal injury Effects 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62380304P | 2004-10-28 | 2004-10-28 | |
| PCT/US2005/038861 WO2006050057A2 (en) | 2004-10-28 | 2005-10-26 | Methods and compositions using pde4 modulators for treatment and management of central nervous system injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008518924A JP2008518924A (ja) | 2008-06-05 |
| JP2008518924A5 true JP2008518924A5 (enExample) | 2008-11-27 |
Family
ID=36319648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007539148A Abandoned JP2008518924A (ja) | 2004-10-28 | 2005-10-26 | 中枢神経系損傷の治療及び管理のためのｐｄｅ４モジュレータを使用する方法及び組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20060106085A1 (enExample) |
| EP (1) | EP1811992A2 (enExample) |
| JP (1) | JP2008518924A (enExample) |
| KR (1) | KR20070085454A (enExample) |
| CN (1) | CN101309585A (enExample) |
| AR (1) | AR052223A1 (enExample) |
| AU (1) | AU2005302523A1 (enExample) |
| BR (1) | BRPI0518062A (enExample) |
| CA (1) | CA2585423A1 (enExample) |
| IL (1) | IL182825A0 (enExample) |
| MX (1) | MX2007005040A (enExample) |
| PE (1) | PE20061167A1 (enExample) |
| WO (1) | WO2006050057A2 (enExample) |
| ZA (1) | ZA200704251B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| WO2007047978A2 (en) * | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| JP5352452B2 (ja) * | 2006-06-06 | 2013-11-27 | メディシノバ， インコーポレイテッド | 置換ピラゾロ［１，５−ａ］ピリジン化合物およびその使用方法 |
| PL2231640T3 (pl) * | 2008-01-24 | 2012-09-28 | Merck Patent Gmbh | Pochodne beta-aminokwasowe do leczenia cukrzycy |
| ES2632979T3 (es) | 2011-01-10 | 2017-09-18 | Celgene Corporation | Formas de dosificación oral de {2-[(1S)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil]-3-oxo-2,3-dihidro-1H-isoindol-4-il}-amida de ácido ciclopropanocarboxílico |
| US8865723B2 (en) | 2012-10-25 | 2014-10-21 | Tetra Discovery Partners Llc | Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury |
| WO2017030892A1 (en) | 2015-08-14 | 2017-02-23 | Reaction Biology Corp. | Histone deacetylase inhibitors and methods for use thereof |
| US20220098257A1 (en) * | 2019-01-23 | 2022-03-31 | Path Therapeutics, Inc. | Methods of Treating Epilepsy via Phosphodiesterase 4 (PDE4) Inhibition |
| EP4281065A1 (en) * | 2021-01-20 | 2023-11-29 | Alto Neuroscience, Inc. | Enhancement of camp signaling as a combination drug strategy for the treatment of depression and related conditions |
| US11999694B2 (en) | 2021-10-29 | 2024-06-04 | Sensorium Therapeutics, Inc. | Delivery of therapeutic alkaloid compounds |
| US12410128B1 (en) | 2022-04-15 | 2025-09-09 | Sensorium Therapeutics, Inc. | Therapeutic alkaloid compounds |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US570302A (en) * | 1896-10-27 | Weighing-machine | ||
| US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4215114A (en) * | 1976-11-12 | 1980-07-29 | The Upjohn Company | Analgesic N-[2-(furyl-methylamino and 2-thienylmethylamino)cycloaliphatic]be |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US5605914A (en) * | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
| US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| KR100263817B1 (ko) * | 1993-11-30 | 2000-08-16 | 윌리암스 로저 에이 | 염증치료용 치환 피라졸일벤젠술폰아미드 |
| IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5703098A (en) * | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
| US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
| US5801195A (en) * | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
| US6518281B2 (en) * | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
| US5728845A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
| US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
| US5658940A (en) * | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
| HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US5798368A (en) * | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| US5929117A (en) * | 1996-08-12 | 1999-07-27 | Celgene Corporation | Immunotherapeutic agents |
| PT1035848E (pt) * | 1997-07-31 | 2003-09-30 | Celgene Corp | Acidos alcano-hidroxamicos substituidos e metodo de reducao dos niveis de tnf alfa |
| US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
| US5874448A (en) * | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
| TR200101504T2 (tr) * | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı. |
| SE9803710L (sv) * | 1998-09-25 | 2000-03-26 | A & Science Invest Ab | Användning av vissa substanser för behandling av nervrotsskador |
| US20030087962A1 (en) * | 1998-10-20 | 2003-05-08 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| US6177077B1 (en) * | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
| CA2361806C (en) * | 1999-03-18 | 2012-03-13 | Celgene Corporation | Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels |
| US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
| US6699899B1 (en) * | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
| US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US20040038874A1 (en) * | 2002-08-22 | 2004-02-26 | Osemwota Omoigui | Method of treatment of persistent pain |
-
2005
- 2005-10-26 EP EP05814094A patent/EP1811992A2/en not_active Withdrawn
- 2005-10-26 AU AU2005302523A patent/AU2005302523A1/en not_active Abandoned
- 2005-10-26 ZA ZA200704251A patent/ZA200704251B/xx unknown
- 2005-10-26 KR KR1020077011855A patent/KR20070085454A/ko not_active Withdrawn
- 2005-10-26 BR BRPI0518062-7A patent/BRPI0518062A/pt not_active IP Right Cessation
- 2005-10-26 JP JP2007539148A patent/JP2008518924A/ja not_active Abandoned
- 2005-10-26 CA CA002585423A patent/CA2585423A1/en not_active Abandoned
- 2005-10-26 WO PCT/US2005/038861 patent/WO2006050057A2/en not_active Ceased
- 2005-10-26 MX MX2007005040A patent/MX2007005040A/es not_active Application Discontinuation
- 2005-10-26 CN CNA2005800452239A patent/CN101309585A/zh active Pending
- 2005-10-27 AR ARP050104509A patent/AR052223A1/es not_active Application Discontinuation
- 2005-10-27 US US11/262,374 patent/US20060106085A1/en not_active Abandoned
- 2005-10-28 PE PE2005001269A patent/PE20061167A1/es not_active Application Discontinuation
-
2007
- 2007-04-26 IL IL182825A patent/IL182825A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008518924A5 (enExample) | ||
| CN102177153B (zh) | 治疗酒精使用障碍，疼痛和其他疾病的药物组合与方法 | |
| ES2217191T5 (es) | Asociacion de un antagonista del receptor cb1 y de sibutramina para el tratamiento de la obesidad. | |
| US5817662A (en) | Substituted amino alkyl compounds | |
| CA2495060A1 (en) | Derivatives of pyrrolo-pyrazines having a kinase inhibitory activity and their biological applications | |
| RU2005103398A (ru) | Производные 7,8,9,10-тетрагидро-6h-азепино-, 6,7,8,9-тетрагидропиридо-и 2,3-дигидро-2h-пирроло-[2,1-b]-хиназолинона | |
| CA2473986A1 (en) | Indazole compounds useful as protein kinase inhibitors | |
| CA2316921A1 (en) | Aryl fused azapolycyclic compounds | |
| JP2006514021A5 (enExample) | ||
| CA2256227A1 (en) | Method of treating psychiatric conditions | |
| CN1155276A (zh) | 酶抑制剂 | |
| CN115103677A (zh) | Atr抑制剂与parp抑制剂的组合的用途 | |
| EP1423146A1 (fr) | Composition pour le traitement de la maladie de parkinson contenant un antagoniste du recepteur cb1 et un produit qui active la neurotransmission dopaminergique dans le cerveau | |
| EP0623133A1 (en) | Substituted amino alkyl compounds | |
| JP2006519875A5 (enExample) | ||
| WO1999058117A1 (fr) | Utilisation de composes reduisant l'apoptose | |
| Welmaker et al. | Synthesis and 5-Hydroxytryptamine (5-HT) activity of 2, 3, 4, 4a-Tetrahydro-1H-pyrazino [1, 2-a] quinoxalin-5-(6H) ones and 2, 3, 4, 4a, 5, 6-Hexahydro-1H-pyrazino [1, 2-a] quinoxalines | |
| US20060100263A1 (en) | Antipyretic compositions and methods | |
| HRP20110650T1 (hr) | DERIVATI 1,2,3,4-TETRAHIDROPIROLO[1,2-a]PIRAZIN-6-KARBOKSAMIDA I 2,3,4,5-TETRAHIDROPIROLO[1,2-a]DIAZEPIN-7-KARBOKSAMIDA, NJIHOVO DOBIVANJE I UPOTREBA U TERAPIJI | |
| AU2003289898A1 (en) | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia | |
| AR052223A1 (es) | Metodods y composiciones que utilizan moduladores de pde4 para eltratamiento y el manejo de lesiones del sistema nervioso central | |
| ZA200507322B (en) | Selective cytokine inhibitory drugs for treating disorders of the central nervous system | |
| US5935980A (en) | Use of pyrrolidine derivatives in the treatment of alcoholism | |
| Monti et al. | Sleep and waking in 5, 7-DHT-lesioned or (−)-pindolol-pretreated rats after administration of buspirone, ipsapirone, or gepirone | |
| WO2010043787A1 (fr) | Utilisation du 4-(3-[hexahydrocyclopenta[c]pyrrol-i(ih)- yl]propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil |